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early treatment response evaluation in 82 (67.21%) of the patients, for staging in 
65 (53.28%) patients, late treatment responseevaluation in 48 (39.34%) patients, 
for restaging in 40 (32.79%) patients. PET/CT was not used for diagnosis and 
radiation treatment response evaluation. Major histologic subtype was found to 
be infiltrating ductal carcinoma (IDC) (91%). liver was the most common 
metastatic site among all (41 patients) 85.37% in 35 patients, lung in 30 patients 
(73.17%), bone in 25 patients (60.98%), around 3 patients were having lesions in 
brain, adrenal and ovaries, around (4.88%) 2 patients were presented with lesion 
in atrium. Recurrence was present in 31(76%) patients, chest wall invasion in 10 
patients (24%). Maximum number of patients around 21 patients had lesions in 
ipsilateral axillary nodes (51.22%), 16 in supraclavicular nodes (39.02%) and 13 
patients (31.71%) in contralateral nodes. Treatment plan was altered in 55 
patients (45.08%), whereas supported in 67 patients (54.92%). CONCLUSIONS: The 
clinical utility of PET/CT may lead to a change in the routine diagnostic 
algorithm and follow-up protocols for patients with cancer by providing correct 
and early diagnosis of recurrence as well as by establishing its precise 
significance for further clinical management.  
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OBJECTIVES: A lot of studies regarding medication errors are reported and 
published worldwide. We also face a big challenge of medication errors in our 
country. This study aims to explore the types of medication errors in drug 
administration in a large teaching hospital which is a reflection of the 
medication errors in the whole country. METHODS: Trainee Pharmacists from 3 
different batches of Pharmacy in my supervision were assigned to examine the 
errors in different clinical units of the hospital. The study was based on their 
personal monitoring and patients’ interviews regarding the medication 
administration. The results were collected from 1900 patients and the study 
period was from June, 2008 to November, 2010. RESULTS: We had detected 910 
medication errors out of 1900 patients only in drug administration. In each 
category the medication errors were omission: 387(42.5%), time: 291(32%), 
unauthorized drug: 89(9.8%), wrong rate: 70(7.7%), wrong route: 56(6%) and wrong 
dosage form: 17(2%). The health care professionals involved in these medication 
errors were nurses and the reason was lack of hospital Pharmacists in each 
nursing unit. CONCLUSIONS: Different areas in our country and other 
developing countries might have these problems/results. There is a dire need for 
the induction of hospital Pharmacists in the health care system to overcome 
these types of medication errors which leads to about 40% accidents and 
incidents in drug administration. Nurses involved in these medication errors 
should be trained for proper use and administration of the drugs to the in-
patients in particular. This study also indicates that this type of practice is the 
reflection of state and regulatory affairs in the country and this is a warning for 
all developing countries.  
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OBJECTIVES: A common limitation of the peer-reviewed literature is failure to 
establish whether a condition precedes or follows disease diagnosis. If disease 
diagnosis comes first, the condition is either a comorbidity or consequence of 
the disease, whereas if the condition precedes disease diagnosis, it may be a risk 
factor. Our objective was to develop an algorithm for appropriate classification of 
risk factors, comorbidities, and consequences of disease to enable accurate 
assessment of the literature. METHODS: We established the following procedure 
to identify risk factors in articles retrieved through our literature search: 1) 
exclude cross-sectional studies as potential sources of risk factor data because 
they cannot establish the necessary temporal sequence; 2) if the terms ‘risk 
factor’ or ‘incidence’ are present in the remaining articles, include only those 
that: a) report on a population followed over time; b) contain baseline data 
indicating absence of signs/symptoms of the disease of interest at study onset; 
and c) have conducted statistical analyses demonstrating associations between 
individual baseline factors and the disease. If these requisites are not met, 
signs/symptoms present at study onset should be classified as comorbid 
conditions. Conditions arising as a result of the condition may be classified as 
disease consequences. RESULTS: We systematically applied our algorithm to 100 
peer-reviewed articles in clinically focused journals retained for inclusion after 
screening. The algorithm allowed for accurate classification of risk factors (ie, 
underlying conditions that predispose a patient to development of the disease), 
comorbidities (ie, conditions that complicate disease progress), and 
consequences of the disease (ie, events shown to be statistically related to the 
disease and occurring after disease onset). CONCLUSIONS: We have developed 
an algorithm that accurately differentiates among risk factors, comorbidities, 
and consequences of a disease. This tool will aid in the accurate assessment of 
clinical literature when conducting systematic reviews.  
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OBJECTIVES: In the biopharmaceutical industry, site-based studies are the norm 
for evaluating drug safety and efficacy. Recently patient-centered studies (PCSs) 
have gained popularity. These studies offer advantages over site-based studies, 
but present unique challenges. This abstract seeks to describe the patient-
centered approach and associated challenges and opportunities. METHODS: This 
descriptive study reviews operational and design issues of PCSs and discusses 
utility, advantages, and challenges. RESULTS: PCSs revolve around patients. 
They use an open-enrollment model whereby all eligible patients can self-enroll 
directly, thereby maximizing enrollment. Enrollment is not limited to patients 
treated at particular study sites. These studies typically employ a single site and 
“virtual” study coordinating center to screen/enroll patients and collect data, 
thus reducing site costs. PCSs are used extensively for pregnancy registries and 
other rare-exposure/disease registries, and more recently for clinical trials. This 
unique approach requires buy-in from regulatory agencies and IRBs. Recruitment 
activities should cast a wide net using various means targeted to the population 
(e.g., internet and social media recruitment sources for younger patients; 
television, radio, or print media for older patients). Streamlined patient 
screening, informed consent (e.g., on-line consent or waivers of written consent), 
and data collection processes are essential. Retention is facilitated by engaging 
participants in the reporting process, minimizing reporter burden, and providing 
ongoing support using various means targeted to the population (e.g., internet or 
mobile apps for younger patients and human support through coordinating 
centers for older patients). It may also be critical to obtain medical release to 
verify patient-reported medical data from treating physicians. However, 
discrepancies between patient-reported and physician-reported data may pose 
challenges in analyses and reporting. CONCLUSIONS: PCSs offer advantages 
such as maximizing enrollment and reducing site costs, but pose regulatory, 
operational, and analytic challenges. Researchers opting to employ PCSs must 
weigh challenges versus opportunities in the design phase.  
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OBJECTIVES: Various methods are used to monitor safety of drug exposures in 
pregnancy, including prospective pregnancy registries, longitudinal database 
studies, and case-control studies. This abstract seeks to evaluate these approaches 
and examine impact on interpretation of results. METHODS: Study designs for the 
three types of pregnancy monitoring studies were examined to determine strengths 
and limitations in effectively monitoring drug safety in pregnancy and the types of 
conclusions that can meaningfully be drawn from each. RESULTS: Pregnancy 
registries are prospective studies with active data collection from reliable sources 
providing detailed, quality data on exposure and outcome. Their voluntary nature 
can lead to selection bias and a lengthy enrollment period may be needed to reach 
sufficient sample size/power. Longitudinal database studies are population based 
and offer timely and cost-efficient results, but often require complex linkage of 
multiple databases. Misclassification bias can occur because critical variables 
(exposure and outcome) may lack precision/detail. Case-control studies begin with 
the outcome of interest and retrospectively assess drug exposure offering 
substantial statistical power to identify teratogens among relatively rare exposures, 
but are subject to recall bias. Only registries are useful in monitoring safety early in 
the drug lifecycle. Pregnancy registries can detect major teratogenic effects, but 
have limited power to detect risk of specific birth defects. Database studies can 
detect major teratogenic effects and due to their large size/power may also detect 
risk of specific defects. Both approaches can assess other outcomes. Case-control 
studies provide insights into the strength of association between exposure and a 
specific defect, but cannot be used to estimate birth defect prevalence or other 
outcomes. CONCLUSIONS: All three approaches are viable for studying drug safety 
in pregnancy, but differ in the types of conclusions that may be drawn. In choosing 
a design, it is important to consider study objectives and outcomes of interest.  
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OBJECTIVES: Naturally occurring catastrophic events not only disrupt economic 
activity but also impact access to essential health services. The purpose of this 
study is to quantify the long-term impact of Hurricane Katrina on continuously-
eligible epilepsy patients’ health care utilization pre-and post-Hurricane Katrina 
(August 29, 2004-August 28, 2007). METHODS: This study was a population-based 
retrospective analysis of the Louisiana Medicaid database. Frequency counts of 
demographic variables age, gender, race and region were computed. Segmented 
regression analysis was applied to the longitudinal data to analyze changes in 
emergency room (ER) utilization, the number of patients receiving anti-epileptic 
medication, the total number of prescriptions utilized and the average cost of 
pharmacy claims. In effect, the dependent variables were regressed against 1) 
total time (months); 2) Katrina as a discrete event; and 3) time post-Katrina 
(months). RESULTS: A total of 1371 epileptic patients in the Louisiana Medicaid 
population was found of which 2/3rds were 18-64 years of age, 49% African-
American and 53.1% were males. Patients were primarily from Baton Rouge 
(44%), New Orleans (36%) and Acadiana (21%). Results of segmented regression 
analysis revealed that ER utilization was significantly related to all three time 
variables. Katrina as a discrete event was statistically significant in relation to 
the number of epileptic patients receiving prescriptions and the number of 
prescriptions utilized, whereas the average cost per prescription claim was 
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  A17 
 
 
related to both total time and time after Katrina. CONCLUSIONS: Hurricane 
Katrina was found to be a key factor in the significant decrease in the number of 
patients that received anti-epileptic medications post-Hurricane Katrina. This 
may also explain why there were significant decreases in the numbers of ER 
visits, anti-epileptic medications obtained and the average cost of paid claims for 
anti-epileptic drugs. In effect, Katrina had both short- and long-term negative 
effects on epileptic patients’ access to care.  
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OBJECTIVES: Hurricane Katrina was the deadliest hurricane in the United States 
in seven decades and the most expensive natural disaster in American history. 
The aftermath of this catastrophic event has provided a window to quantify its 
impact on continuously eligible epilepsy patients in the Louisiana Medicaid 
population with respect to outpatient visits, inpatient visits and changes in 
providers specialty categories pre- and post Hurricane Katrina (August 29, 2004-
August 28, 2007). METHODS: This study was a population-based retrospective 
analysis of the Louisiana Medicaid database. Segmented regression analysis was 
applied to the longitudinal data to analyze changes in patients with at least one 
outpatient-visit and inpatient visits made by the providers and the average cost 
of the visits. The dependent variables were regressed against 1) total time 
(months); 2) Katrina as a discrete event; and 3) time post-Katrina (months). A chi-
square analysis was performed to determine the change in provider specialty 
categories at α = 0.05 pre and post Hurricane Katrina. RESULTS: Results of 
segmented regression analysis revealed that time variables, total and time post-
Katrina, were significant for the average cost of paid claims submitted by 
outpatient providers. There was no significant increase in number of patients 
with inpatient admissions (npre=97, npost1=119, npost2=137) and no significant 
change in average cost of paid claims submitted by inpatient providers but the 
number of inpatient visits (pre=298, post1=435, post2=567) increased 
significantly. Visits to neurologists decreased by a significant number (npre=147, 
npost1=91, npost2=82) pre- and post-Katrina. Also, the number of primary care 
physicians visits increased from pre- to post-period. CONCLUSIONS: Hurricane 
Katrina may be a key factor in increase in number of inpatient visits made by the 
providers. Decrease of visits to neurologists due to displacement post-Hurricane 
Katrina may be a reason for increasing patient visits to primary care physicians.  
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OBJECTIVES: This study aims to examine vaccine effectiveness (VE) estimates 
used in cost-effectiveness studies that compared the 23-valent pneumococcal 
polysaccharide vaccine (PPSV23) to the 13-valent pneumococcal conjugate 
vaccine (PCV13) for adults, and assess how differences in VE estimates affect the 
estimated incremental cost-effectiveness ratios (ICER). METHODS: A targeted 
literature review was performed to identify cost-effectiveness analyses of PPSV23 
vs. PCV13 in adults. A comparative assessment of input parameter values used in 
these analyses was performed and their relationship to model results was 
examined. RESULTS: Four models that evaluated the cost-effectiveness of 
PPSV23 versus PCV13 in adults were identified. All models estimated that PPSV23 
protected against more vaccine-type infections than PCV13. However, each 
model assumed different VE estimates in preventing invasive pneumococcal 
disease (IPD) and non-bacteremic pneumococcal pneumonia (NBPP). PCV13 VE 
estimates for adults were derived from pediatric clinical efficacy data either 
directly or via Delphi panels. PPSV23 VE estimates were obtained from meta-
analyses of randomized trials or observational studies in adults either directly or 
with Delphi panels. For vaccine-type IPD, base-case VE estimates were relatively 
consistent among the studies for immunocompetent adults (PPSV23: 57%-93%; 
PCV13: 61%-94%) but varied for immunocompromised adults (PPSV23: 0%-18%; 
PCV13: 48%-71%). For vaccine-type NBPP, VE estimates varied for 
immunocompetent adults (PPSV23: 0%-60%; PCV13: 50%-74%) and 
immunocompromised adults (PPSV23: 0%, PCV13: 6%-35%). Model results 
showed that PCV13 had lower ICERs than PPSV23 when PPSV23 efficacy for NBPP 
was assumed to be 0%, while PPSV23 had lower ICERs than PCV13 when PPSV23 
was assumed effective in preventing NBPP in immunocompetent adults. 
CONCLUSIONS: Cost-effectiveness results for adult pneumococcal vaccination 
were highly sensitive to VE estimates. With the absence of head-to-head clinical 
efficacy data comparing PPSV23 to PCV13 and the influence these data have on 
model results, sensitivity analyses are needed when considering potential policy 
implications of these cost-effectiveness studies.  
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OBJECTIVES: As compared to non-diabetics, diabetic patients are more likely to 
be hospitalized with longer hospital stay. A variety of risk adjustment (RA) 
measures are available, which makes it difficult to select the best performing 
measure to predict outcomes. The aim of this study is to compare performance 
of risk adjustment measures to predict in-hospital mortality and length of stay 
(LOS) in diabetic patients. METHODS: A retrospective cross-sectional study was 
conducted using the HCUP Nationwide inpatient Sample (NIS)-2009 data. All 
adults (age >18 years) diagnosed with Diabetes were included in the study. 
Charlson-Deyo Adaptation and Elixhauser Co-morbidity Index were constructed 
using the International Classification of Disease, 9th Revision, Clinical 
Modification (ICD-9-CM). Two proprietary measures (APR-DRG & Disease Staging) 
were compared with comorbidity measures for predicting in-hospital mortality 
and LOS. Logistic regression was used to predict in-hospital mortality and c-
statistics were used to assess the comparative performance of different models. 
Adjusted R2from Linear regression models was compared to do the same for the 
continuous outcome, LOS. RESULTS: The prevalence of diabetes was found to be 
28.2% with mortality rate of 2.09% and median LOS of 2.77 ± 0.01 days. Hospital 
stays were predominantly by white females (<65 years). Models containing APR-
DRG measure outperformed all other measures for both outcomes (in-hospital 
mortality, c-statistics=0.91-0.90 and; LOS, adjusted R2=0.172-0.163). The model 
containing all demographic variables along with APR-DRG and Elixhauser 
comorbidity index outperformed all other models for predicting in-hospital 
mortality (c-statistics=0.91) and LOS (Adjusted R2=0.172). CONCLUSIONS: The 
APR-DRG, being a clinical model, is superior to other comorbidity measures for 
risk-adjusting in-hospital mortality and LOS. Addition of comorbidity measures 
to APR-DRG improves the model performance when predicting in-hospital 
mortality and LOS.  
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OBJECTIVES: To develop a novel metric to evaluate the potential value of 
individualized care using traditional clinical trial data to prioritize patient 
centered outcomes research (PCOR). METHODS: Assume a head to head trial of 2 
treatments (A and B), patients are randomly assigned to either treatment and QA 
and QB are outcomes obtained. The joint distribution (QAB) is not available as 
patients can only be assigned to one treatment. However, the marginal 
distributions of QA and QB, as obtained in a standard clinical trial, represent a 
plausible range of heterogeneous treatment effects. The extent of these marginal 
distributions can be used to form a Jointness-Box (JB) bounding an expected 
range of individual potential outcomes. Graphically, in a plot of QA versus QB , 
where the 45-degree line represents the locus of equality, the JB represents the 
area enveloping the anticipated joint distribution of QA and QB. In our 
development, we examine conditions of JB dominance i.e. if the entire box is 
above or below the 45 degree line, and JB area i.e. proportion of the JB that falls 
above the 45 degree line. We used bootstrap methods, ordered statistics and 
percentile cutoffs to examine the likelihood of JB dominance, and confidence 
intervals for JB area across a range of starting assumptions and distributions. 
RESULTS: We found JB dominance is negatively correlated with the value of 
PCOR. The JB area versus PCOR is concave shaped with maximal PCOR when JB 
area = 0.5. Simulation analysis indicates that for normally distributed trial 
outcomes, JB estimates are conservative in terms of inference about 
heterogeneity, and exhibit maximal accuracy when JB area = 0.5. CONCLUSIONS: 
The JB metric developed allows analysts and decision makers to intuitively 
understand the potential value and impact of exploring heterogeneity within a 
PCOR context.  
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OBJECTIVES: Drug manufacturers often struggle with the decision to include 
patient-relevant outcome measures into clinical trials while also trying to satisfy 
the demands of regulators and payers. In oncologic indications, where the 
diagnosis and management of cancer can have a significant impact on survival 
and patient and quality of life (QoL), more focus is therefore being placed on the 
quality of extended survival for cancer patients. Here, we examine inclusion of 
patient reported outcomes (PROs) as primary or secondary QoL endpoints for the 
top ten oncology indications currently in Phase III development. METHODS: 
Pipeline drug candidates from Adis R&D Insight database were collected with 
clinical development details for all late-phase (Phase II/III or Phase III) drug 
candidates in the top ten oncology indications. Trial details were further 
examined via ClinicalTrials.gov. An analysis was then conducted to determine 
how frequently drug trials are incorporating patient-relevant outcomes into their 
clinical development programs. Results were categorized into five clustered PRO 
categories. RESULTS: Over 140 drug candidates and 304 clinical trials were 
identified. In these trials, only 11 included PROs as a primary endpoint. As 
secondary endpoints PROs were much more common, appearing 184 (60.5%) 
occasions. A total of 54 different PRO endpoints were utilized to measure QoL. 
Generic Non-Cancer measures (9.5%), Specific Non-Cancer measures (9.9%), 
General Cancer-Specific measures (16.1%), Symptom-Specific Cancer measures 
(6.3%), and Unspecified/General measures (18.8%) were utilized by 
manufacturers. EQ-5D was the most commonly specified measure (7.6%), 
followed by EORTC QLQ C30 (6.3%). CONCLUSIONS: Drug manufacturers are 
largely including PROs into oncology trials. However, the selection of measures is 
inconsistent and opportunities still exist to collect further QoL data by including 
PROs in trials where such measures are absent. Aligning the demands of payers, 
physicians and patients would help to incentivize a more standardized inclusion 
of PROs with greater frequently in oncology development programs  
